FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1397-1398 March 27, 2008 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

At a recent meeting to discuss cell-based therapies for cardiovascular disease, a colleague asked, "With intracardiac devices being so successful, why would anybody want to put unknown cells into sick hearts?" Although horse-and-buggy drivers probably made similar comments about the first automobiles, the question bears consideration. After injury, myocardial regeneration occurs slowly, if at all. The hypothesis behind cell-based therapy for cardiac injury is that adding healthy cells to injured myocardium increases the rate of recovery¹ and, in so doing, improves cardiac function and prevents life-threatening arrhythmias. Yet, to date, success with cell therapies has been limited, and under some . . . [Full Text of this Article]

Source Information

From the Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.